Labcorp revised earnings guidance for the full year 2021. The company raised its 2021 full year guidance to 2.0% to 6.5% to reflect the improved recovery in the Diagnostics and Drug Development base businesses, while the COVID-19 Testing contribution remains within the original guidance range provided.